Nab-paclitaxel-based therapy in underserved patient populations: The aboundPs2 study in patients with nsclc and a performance status of 2
Gajra A, Karim NA, Mulford DA, Villaruz LC, Matrana MR, Ali HY, Santos ES, Berry T, Ong TJ, Sanford A, Amiri K, and Spigel DR. Nab-paclitaxel-based therapy in underserved patient populations: The abound.Ps2 study in patients with nsclc and a performance status of 2. Front Oncol 2018; 8:253.
Introduction: The phase II ABOUND.PS2 study (NCT02289456) assessed safety/tolerability of a first-line modified
Methods: Chemotherapy-naive patients with stage IIIB/IV NSCLC and ECOG PS 2 received four cycles of
Results: 11/40 treated patients (27.5%; 95% CI, 14.60-43.89) discontinued chemotherapy induction due to TEAEs; 16/40 (40.0%) continued